RAS Protein Overview
RAS proteins are a family of small GTPases, responsible for transmitting signals within cells. When RAS protein receives a signal, they switch on other protein and starts the process of cell growth, differentiation, and survival. Understanding of how RAS signaling works is pivotal for developing targeted therapies in oncology.
Using RAS for Target Validation in Cancer Research
At Ichor Life Sciences, we offer robust RAS target validation studies to confirm the therapeutic potential of RAS proteins. Our innovative approach integrates structural, biophysical, cell-based, in vitro, and protein purification techniques to deliver powerful data for your drug discovery pipeline. Our scientists utilize high-resolution structural biology, including X-ray crystallography and NMR, to delineate RAS (HRAS, KRAS, NRAS) binding pockets and validate inhibitor interactions. We also utilize Biophysical assays, like Surface Plasmon Resonance (SPR) and Isothermal Titration Calorimetry (ITC), to quantify binding kinetics and specificity. Our cell-based assays, utilizing CRISPR/Cas9 gene editing and RNAi screens in disease-relevant models, assess RAS-driven effects on proliferation, survival, and signaling pathways. Our in vivo models utilizes patient-derived xenografts (PDX) and genetically engineered mouse models (GEMMs) to evaluate RAS function and drug efficacy in physiologically relevant settings. Our validations include PK/PD studies to optimize dosing and validate target engagement.




